Y U So Mad?

The CEO and Founder of Seattle genetics Clay Siegall

Nov
14

The CEO and Founder of Seattle genetics Clay Siegall

A biopharmaceutical company, ultragenyx pharmaceutical.Inc. Which focuses on the production of products for rare and ultra-rare diseases announced the appointment of Mr. clay to the board of directors as from January 30 in the year 2014.Mr siegall and Mr. Fuss are needed by ultragenyx to serve as its independent directors.Dr siegall acknowledged ultragenyxs’growth with its clinical programs and offered to share his expertise for the success of ultragenyx and to importantly help patients with rare and ultra-rare diseases.

Dr. Siegall is the President, Chairman of the board of Directors and also the Chief Executive Officer of Seattle Genetics Inc. which is a biotechnology company that specializes in production and selling of antibody-based therapies for the treatment of cancer. In 1998 Dr. siegall cofounded Seattle genetics, and in 1988 to 1991 he worked for National cancer institute, National Institute of health, from 1991 to 1997 he worked for a pharmaceutical research institute known as Bristol-Myers Squibb. Dr. Siegall also serves as a director in two companies, Mirna Therapeutic and Alder Biopharmaceutical Inc. He got his B.S in zoology in the University of Maryland and a P.H.D in genetics from George Washington University.

Seattle genetics ranks as the largest biotech company in Washington which invests mainly in research and a marketing of new cancer drugs.Siegalls’ ambition is not only in drug development but also to handle all the complexities of international marketing of newer drugs, especially for rare and ultra-rare diseases. Clay Siegall says that he loves making drugs although it’s not easy he keeps pushing on. His strategy is to become a robust entrepreneur and imitates his mentors for his success.

Dr. Siegall built Seattle genetics based on scientific innovation, drug development, and research as well as his passion for helping patients. Under his leadership, the company has developed antibody-drug conjugates (ADCs) for cancer treatment. His motivation to start the company came up from watching his father progress with cancer till his death. He realized that the oncologists had fewer tools and so he wanted to improve the tools. His aim to treat cancer patients and to improve the treatment of cancer for it to be better than it is today.

Dr. Clay has received various awards which include Math and natural sciences, the 2012 Northwest Ernst young entrepreneur of the year and also the 2013 University of Maryland Alumnus of the year for the computer. Siegall has also authored more than 70 publications and holds 15 patents. His work is an excellent motivation to many people.

Clay Siegall Discusses About The Success Of Seattle Genetics

May
15

Clay Siegall is the founder and CEO of a renowned biotech company, Seattle Genetics. Recently, he discussed about his journey with the company. When he was growing up, he developed a keen interest in the field of medicine. He was also thrilled by the power of technology. While studying zoology at the University of Maryland, he experienced the pain of seeing his father struggle with cancer. This situation fueled his desire to explore other options of developing cancer treatment. To this end, he founded Seattle genetics through which he focuses on the development of cancer therapies that protect normal cells from damage. Clay Siegall attributes the company’s success to the sales professionals who have extensive experience in the biotech technology and are highly knowledgeable about the company’s products. He said that success comes with an undying passion to work intensely.

In addition, Dr. Clay Siegall serves as Seattle Genetics’ president. He studied genetics at the George Washington University where he earned his PhD. He applies his vast knowledge in genetics and combines it with vigorous research and scientific innovation to come up with the most appropriate cancer therapies. Seattle Genetics pioneered the development of antibody-drug conjugates (ADCs), with its first drug, ADCETRIS, being approved by the FDA. The company collaborates with Takeda Pharmaceutical Company to sell ADCETRIS to more than 65 countries. The company also partners with other biotech companies in the production and licensing of technologies used in the development of ADCETRIS.

Siegall has worked hard to ensure that the corporation has adequate funds to run its operations. The executive has secured over $1.2 billion from public and private sources, including the company’s initial public offering of 2001. He seeks to ensure that ADCETRIS is approved in more countries. Previously, he rendered his services for Bristol-Myers Squibb Pharmaceutical Research Institute. He has also worked for the National Cancer Institute as well as the National Institutes of Health. Presently, Siegall sits to the boards of Washington Roundtable, Alder BioPharmaceuticals and Ultragenyx Pharmaceutical. He is the recipient of the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. In 2012, Clay was presented with the Pacific Northwest Ernst & Young Entrepreneur of the Year. Over the years, he has authored over 70 publications. Notably, Clay holds 15 patents.